Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1378/chest.38.2.217 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modelling post-chemotherapy stem cell dynamics in the bone marrow niche of AML patients.
Sci Rep
October 2024
Institute for Computational Biomedicine-Disease Modeling, RWTH Aachen University, Aachen, Germany.
Acute myeloid leukemia (AML) is a stem cell-driven malignancy of the blood forming (hematopoietic) system. Despite of high dose chemotherapy with toxic side effects, many patients eventually relapse. The "7+3 regimen", which consists of 7 days of cytarabine in combination with daunorubicin during the first 3 days, is a widely used therapy protocol.
View Article and Find Full Text PDFCD38, CD39, and BCL2 differentiate disseminated forms of high-grade B-cell lymphomas in biological fluids from Burkitt lymphoma and diffuse large B-cell lymphoma.
Cytometry B Clin Cytom
November 2024
Department of Biological Hematology, St Eloi Hospital, Montpellier University Hospital, Montpellier, France.
High-grade B-cell lymphomas (HGBCL) represent a heterogeneous group of very rare mature B-cell lymphomas. The 4th revised edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (WHO-HAEM) previously defined two categories of HGBCL: the so-called double-hit (DHL) and triple-hit (THL) lymphomas, which were related to forms harboring MYC and BCL2 and/or BCL6 rearrangements, and HGBCL, NOS (not otherwise specified), corresponding to entities with intermediate characteristics between diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), without rearrangement of the MYC and BCL2, and/or BCL6 genes. In the 5th edition of the WHO-HAEM, DHL with MYC and BCL2 rearrangements or THL were reassigned as DLBCL/HGBCL with MYC and BCL2 rearrangements (DLBCL/HGBL-MYC/BCL2), whereas the category HGBCL, NOS remains unchanged.
View Article and Find Full Text PDFPlant-derived extracts and metabolic modulation in leukemia: a promising approach to overcome treatment resistance.
Front Mol Biosci
July 2023
Grupo de Inmunobiología y Biología Celular, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, Colombia.
Leukemic cells acquire complex and often multifactorial mechanisms of resistance to treatment, including various metabolic alterations. Although the use of metabolic modulators has been proposed for several decades, their use in clinical practice has not been established. Natural products, the so-called botanical drugs, are capable of regulating tumor metabolism, particularly in hematopoietic tumors, which could partly explain the biological activity attributed to them for a long time.
View Article and Find Full Text PDFCheckpoint Inhibitors in Acute Myeloid Leukemia.
Biomedicines
June 2023
Division of Hematology and Stem Cell Transplantation, Udine Hospital, 33100 Udine, Italy.
The prognosis of acute myeloid leukemia (AML) remains unsatisfactory. Among the reasons for the poor response to therapy and high incidence of relapse, there is tumor cell immune escape, as AML blasts can negatively influence various components of the immune system, mostly weakening T-cells. Since leukemic cells can dysregulate immune checkpoints (ICs), receptor-based signal transductors that lead to the negative regulation of T-cells and, eventually, to immune surveillance escape, the inhibition of ICs is a promising therapeutic strategy and has led to the development of so-called immune checkpoint inhibitors (ICIs).
View Article and Find Full Text PDFAutolysosomal activation combined with lysosomal destabilization efficiently targets myeloid leukemia cells for cell death.
Front Oncol
February 2023
Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Introduction: Current cancer research has led to a renewed interest in exploring lysosomal membrane permeabilization and lysosomal cell death as a targeted therapeutic approach for cancer treatment. Evidence suggests that differences in lysosomal biogenesis between cancer and normal cells might open a therapeutic window. Lysosomal membrane stability may be affected by the so-called ' characterized by higher lysosomal abundance and activity and more intensive fusion or interaction with other vacuole compartments.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!